植田　真一郎 (ウエダ　シンイチロウ)

Ueda Shinichiro

写真a

職名

教授

科研費研究者番号

80285105
このページの先頭へ▲

現在の所属組織 【 表示 ／ 非表示 】

  • 専任   琉球大学   医学研究科   教授  

このページの先頭へ▲

留学歴 【 表示 ／ 非表示 】

  • 1991年10月
    -
    1996年07月

    Department of Medicine& Therapeutics Western Infirmary,University of Glasgow,Scotland, UK  

このページの先頭へ▲

取得学位 【 表示 ／ 非表示 】

  • 横浜市立大学 -  医学博士  その他 / その他

このページの先頭へ▲

職歴 【 表示 ／ 非表示 】

  • 2001年12月
    -
    継続中

      琉球大学　医学研究科　教授  

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • ヒト血管内皮機能

  • 平滑筋機能,心血管薬薬効評価のための代替エンドポイントの開発,降圧利尿薬ランダム化臨床試験,代謝症候群における血管機能

  • インスリン感受性への治療介入と評価

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Association between contrast-induced nephrotoxicity and contrast enhanced computed tomography followed by endoscopic retrograde cholangiopancreatography.

    Shinoura S, Tokushige A, Chinen K, Mori H, Kato S, Ueda S

    European journal of radiology ( European Journal of Radiology )  129   109074 - 109074   2020年08月 [ 査読有り ]

    掲載種別: 研究論文（学術雑誌）

    　概要を見る

    PURPOSE: To determine if endoscopic retrograde cholangiopancreatography (ERCP) performed within 72 h after contrast enhanced computed tomography (CECT) increases contrast-induced nephrotoxicity (CIN) risk in patients with abdominal complaints. METHOD: This single-center retrospective cohort study included consecutive adult patients with abdominal complaints who underwent CECT between October 1, 2016, and June 30, 2019 at an emergency department (ED). CIN was diagnosed based on serum creatinine (SCr) level >0.5 mg/dL within 72 h after CECT or that increased >25 % compared to pre-CECT level. Logistic regression analysis was performed to determine independent risk factors for CIN, including age, sex, body mass index, comorbidities, medication, pre-CECT SCr level >1.5 mg/dL, and ERCP performed within 72 h after CECT. For persistent CIN, SCr level was obtained after 3 months at the earliest and compared to data obtained within 72 h after ERCP and CECT. RESULTS: Of 1457 patients with CECT, 90 (6.2 %) underwent ERCP within 72 h after CECT and 93 (6.4 %) developed CIN. Multivariate analysis revealed that ERCP performed within 72 h after CECT (odds ratio, 3.31; 95 % confidence interval, 1.74, 6.29; p < 0.001) and pre-CECT SCr level >1.5 mg/dL (odds ratio, 9.86; 95 % confidence interval, 5.08, 19.2; p < 0.001) were independent risk factors for CIN. Of 93 patients with CIN, 10 (11 %) had persistent CIN. No specific factors were correlated with persistent CIN in the 3-month time frame. CONCLUSION: ERCP performed within 72 h after CECT and pre-CECT SCr level >1.5 mg/dL are associated with CIN development.

    • この論文にアクセスする
      DOI
    • 関連情報を調べる
      PubMed

  • Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A.

    Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Han Y, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y

    Hypertension research : official journal of the Japanese Society of Hypertension ( Hypertension Research )  43 ( 8 ) 781 - 790   2020年08月 [ 査読有り ]

    掲載種別: 研究論文（学術雑誌）

    • この論文にアクセスする
      DOI
    • 関連情報を調べる
      PubMed

  • Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).

    Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, Sata M, Ueda S, Oyama JI, Kitakaze M, Murohara T, Node K, CANDLE Trial Investigators.

    ESC heart failure ( ESC Heart Failure )  7 ( 4 ) 1585 - 1594   2020年08月 [ 査読有り ]

    掲載種別: 研究論文（学術雑誌）

    • この論文にアクセスする
      DOI
    • 関連情報を調べる
      PubMed

  • Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.

    Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S

    Cardiovascular diabetology ( Cardiovascular Diabetology )  19 ( 1 ) 89   2020年06月 [ 査読有り ]

    掲載種別: 研究論文（学術雑誌）

    • この論文にアクセスする
      DOI
    • 関連情報を調べる
      PubMed

  • Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.

    Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K

    Journal of diabetes investigation ( Journal of Diabetes Investigation )    2020年06月 [ 査読有り ]

    掲載種別: 研究論文（学術雑誌）

    　概要を見る

    AIMS/INTRODUCTION: Recent clinical trials on sodium-glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. MATERIALS AND METHODS: The effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized (EMBLEM) trial in patients with type 2 diabetes and cardiovascular disease showed empagliflozin treatment for 24 weeks had no effect on peripheral endothelial function measured by reactive hyperemia peripheral arterial tonometry. This post-hoc analysis of the EMBLEM trial included a detailed evaluation of the effects of empagliflozin on peripheral endothelial function in order to elucidate the clinical characteristics of responders or non-responders to treatment. RESULTS: Of the 47 patients randomized into the empagliflozin group, 21 (44.7%) showed an increase in the reactive hyperemia index (RHI) after 24 weeks of intervention, with no apparent difference in the clinical characteristics between patients whose RHI either increased (at least >0) or did not increase. There was also no obvious difference between the treatment groups in the proportion of patients who had a clinically meaningful change (≥15%) in log-transformed RHI. No correlation was found between changes in RHI and clinical variables, such as vital signs and laboratory parameters. CONCLUSIONS: Treatment with empagliflozin for 24 weeks in patients with type 2 diabetes and cardiovascular disease did not affect peripheral endothelial function, and was not related to changes in clinical variables, including glycemic parameters. These findings suggest that the actions of sodium-glucose cotransporter 2 inhibitors other than direct improvement in peripheral endothelial function were responsible, at least in the early phase, for the clinical benefits found in recent cardiovascular outcome trials.

    • この論文にアクセスする
      DOI
    • 関連情報を調べる
      PubMed

全件表示 >>

このページの先頭へ▲

著書 【 表示 ／ 非表示 】

このページの先頭へ▲

MISC（その他業績・査読無し論文等） 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

研究発表等の成果普及活動 【 表示 ／ 非表示 】

このページの先頭へ▲

科研費獲得情報 【 表示 ／ 非表示 】

このページの先頭へ▲

その他研究費獲得情報 【 表示 ／ 非表示 】

  • 臨床研究プロフェッショナル育成プログラムの作成

    研究費種類: 公的研究費（省庁・独法・大学等）  参画方法: 研究代表者

    研究種別: 研究助成  事業名: 中央IRB推進事業

    研究期間: 2020年04月  -  2021年03月 

    代表者: 植田 真一郎  連携研究者: 植田真一郎 山中竹春 志賀剛 吉田雅幸 池原由美  資金配分機関: 日本医療研究開発機構

このページの先頭へ▲